A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles

Sorbe,Bengt; Graflund,Marianne; Nygren,Lisa; Horvath,György

doi:10.3892/ol.2013.1146

A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles

Authors:
- Bengt Sorbe
- Marianne Graflund
- Lisa Nygren
- György Horvath
View Affiliations

Affiliations: Department of Oncology, University Hospital, Örebro, Sweden, Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
Published online on: January 22, 2013 https://doi.org/10.3892/ol.2013.1146
Pages: 1140-1148

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to compare the toxicity profiles of docetaxel administered on a weekly schedule and the standard three-week schedule in the treatment of advanced primary ovarian carcinoma. Eligible patients were treated with intravenous docetaxel (30 mg/m2) on days 1, 8 and 15, and carboplatin (AUC 5) on day 1 or with docetaxel (75 mg/m2) and carboplatin (AUC 5) on day 1; Q21 days for 6 cycles. This study was a pooled study of two primary phase II studies. A total of 108 patients received the weekly schedule and 59 patients received the three-week schedule. All patients were evaluated for toxicity. The overall response rate was 79% and the biochemical response 93% for the weekly schedule. The median overall survival rate was 35.3 months. Neutropenia was significantly more common (ANOVA; p<0.0001) in the three-week group than in the weekly group during all six courses of chemotherapy. Fever and infections were also more common in this group. Thrombocytopenia and anemia were slightly more common in the weekly group. Fatigue, epiphora, nail changes and taste disturbances were specific side-effects following weekly docetaxel. Peripheral sensory neuropathy (grade 1-2) increased with every cycle of treatment, but in a similar manner in the two groups. Grade 3-4 neuropathy was not recorded. Oral mucositis and myalgia were two side‑effects associated with the three-week schedule. Nausea and vomiting, diarrhea and dyspnea were a limited problem in both groups. Cardiac toxicity was rare and did not differ between the two docetaxel schedules. The weekly administration was favored due to the lower rates of neutropenia, fever, infections, oral mucositis and myalgia. However, epiphora and nail changes were specific side-effects of the weekly treatment. Both regimens appeared to be rather well tolerated with similar compliance (66 and 70%) with regard to completion of the planned six courses of chemotherapy.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, et al: GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CaseBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010
2	McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
3	Copeland LJ, Bookman M and Trimble E: Gynecologic Oncology Group Protocol GOG 182-ICON5. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol. 90:S1–S7. 2003. View Article : Google Scholar : PubMed/NCBI
4	Safra T, Menczer J, Bernstein RM, et al: Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. Gynecol Oncol. 114:215–218. 2009. View Article : Google Scholar
5	Sehouli J, Stengel D, Mustea A, et al: Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother Pharmacol. 61:243–250. 2008. View Article : Google Scholar : PubMed/NCBI
6	Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 374:1331–1338. 2009. View Article : Google Scholar : PubMed/NCBI
7	Kavanagh JJ: Docetaxel in the treatment of ovarian cancer. Oncology. 16:73–81. 2002.PubMed/NCBI
8	Katsumata N: Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer. 89:S9–S15. 2003. View Article : Google Scholar : PubMed/NCBI
9	Vasey PA, Jayson GC, Gordon A, et al: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 96:1682–1691. 2004. View Article : Google Scholar : PubMed/NCBI
10	Kushner DM, Connor JP, Sanchez F, et al: Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. Gynecol Oncol. 105:358–364. 2007. View Article : Google Scholar : PubMed/NCBI
11	Tinker AV, Gebski V, Fitzharris B, et al: Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel - ANZGOG 02-01. Gynecol Oncol. 104:647–653. 2007. View Article : Google Scholar : PubMed/NCBI
12	Gupta D, Owers RL, Kim M, et al: A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol. 113:327–330. 2009. View Article : Google Scholar : PubMed/NCBI
13	Safra T, Bernstein Molho R, Menzcher J, et al: A feasibility study of weekly docetaxel with capecitabine in ovarian cancer: a promising combination of two active drugs with a potential for synergism. Chemotherapy. 55:298–302. 2009. View Article : Google Scholar : PubMed/NCBI
14	Terauchi F, Hirano T, Taoka H, et al: Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistent relapsed ovarian cancer: a phase I study. Int J Clin Oncol. 8:348–351. 2003. View Article : Google Scholar : PubMed/NCBI
15	Berkenblit A, Seiden MV, Matulonis UA, et al: A phase II trial of weekly docetaxel in patients with platinum-resitent epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 95:624–631. 2004. View Article : Google Scholar : PubMed/NCBI
16	Komiyama S, Tsuji H, Asai S, et al: A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer. Eur J Gynaecol Oncol. 6:299–302. 2005.PubMed/NCBI
17	Sorbe B, Graflund M, Horvath G, Swahn M, Boman K, Bangshöj R, Lood M and Malmström H: Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer. Int J Gynecol Cancer. 22:47–53. 2012. View Article : Google Scholar
18	Sorbe B, Graflund M, Horvath G, Swahn M, Boman K, Bangshöj R, Lood M and Malmström H: A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation. Int J Oncol. 40:773–781. 2012.
19	Calvert AH, Newell DR, Gunbrell LA, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 7:1748–1756. 1989.PubMed/NCBI
20	Cockcroft DW and Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 16:31–41. 1976. View Article : Google Scholar : PubMed/NCBI
21	Green S and Weiss GR: Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 10:239–253. 1992. View Article : Google Scholar : PubMed/NCBI
22	Rustin GJ, Marples M and Nelstrop AE: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res. 10:3919–3926. 2004. View Article : Google Scholar : PubMed/NCBI
23	National Institute of Health: Common Terminology Criteria for Adverse Events (Version 3.0). National Institute of Health; Washington, DC: 2003
24	Fayers P, Aaronson N, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual. 3rd edition. EORTC publications; Brussels, Belgium: 2001
25	Micha JP, Goldstein BH, Rettenmaier MA, et al: A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 17:771–776. 2007. View Article : Google Scholar : PubMed/NCBI
26	Penson RT, Dizon DS, Cannistra SA, et al: Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 28:154–159. 2010. View Article : Google Scholar : PubMed/NCBI
27	Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 26:1642–1649. 2008.
28	Esmaeli B, Hidaji L, Adinin RB, et al: Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 98:504–507. 2003. View Article : Google Scholar : PubMed/NCBI
29	Oishi T, Kigawa J, Fujiwara K, et al: A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. Gynecol Oncol. 90:421–424. 2003. View Article : Google Scholar : PubMed/NCBI
30	Paul LJ and Cohen PR: Paclitaxel-associated subungual pyogenic granuloma: report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent and beneath the nail. J Drugs Dermatol. 11:262–268. 2012.
31	Bezjak A, Tu D, Bacon M, et al: Quality of life in ovarian cancer patients: Comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in randomized study. J Clin Oncol. 22:4595–4603. 2004. View Article : Google Scholar : PubMed/NCBI
32	Souglakos J, Kotsakis A, Kouroussis C, et al: Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors. Cancer. 95:1326–1333. 2002. View Article : Google Scholar : PubMed/NCBI
33	Greimel ER, Bjelic-Radisic V, Pfisterer J, et al: Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol. 24:579–586. 2006. View Article : Google Scholar
34	Schwarz R and Hinz A: Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer. 37:1345–1351. 2001. View Article : Google Scholar : PubMed/NCBI
35	Almadrones L, McGuire DB, Walczak JR, et al: Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. Oncol Nurs Forum. 31:615–623. 2004. View Article : Google Scholar
36	Wenzel L, Huang HQ, Monk BJ, et al: Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 23:5605–5612. 2005. View Article : Google Scholar : PubMed/NCBI